Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor occupancy, and intrinsic activity on the receptor. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaacson, Stuart H., Hauser, Robert A., Pahwa, Rajesh, Gray, David, Duvvuri, Sridhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366643/
https://www.ncbi.nlm.nih.gov/pubmed/37497384
http://dx.doi.org/10.1016/j.prdoa.2023.100212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366643/
https://www.ncbi.nlm.nih.gov/pubmed/37497384
http://dx.doi.org/10.1016/j.prdoa.2023.100212

Ejemplares similares